Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- William Seger, MD
Benchmark Research, Fort Worth, TX
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Benchmark Research - Sacramento
Sacramento, California, United States
- Clinical Research of South Florida
Coral Gables, Florida, United States
- Meridian Clinical Research
Savannah, Georgia, United States
- Heartland Research Associates, Llc
Wichita, Kansas, United States
- Benchmark Research
Metairie, Louisiana, United States
- Meridian Research
Bellevue, Nebraska, United States
- Meridian Clinical Research
Omaha, Nebraska, United States
- Meridian Research
Dakota Dunes, South Dakota, United States
- Benchmark Reseach
Austin, Texas, United States
- Benchmark Research - Fort Worth
Fort Worth, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2014
- Primary completion
- 31 May 2015
- Completion
- 31 May 2015
- Last update posted
- 27 Oct 2016
- Registered enrollment
- 1,350
- Registry id
- NCT02290509
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.